Aardvark Therapeutics’ (AARD) Outperform Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada restated their outperform rating on shares of Aardvark Therapeutics (NASDAQ:AARD) in a research note issued to investors on Tuesday,Benzinga reports. Royal Bank of Canada currently has a $21.00 price target on the stock.

Other equities research analysts also recently issued research reports about the stock. Morgan Stanley assumed coverage on shares of Aardvark Therapeutics in a research report on Monday, March 10th. They set an “overweight” rating and a $29.00 price objective for the company. Bank of America boosted their price objective on Aardvark Therapeutics from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Thursday, March 27th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $50.00 price target on shares of Aardvark Therapeutics in a report on Tuesday.

Aardvark Therapeutics Trading Down 7.1 %

Shares of AARD opened at $8.69 on Tuesday. Aardvark Therapeutics has a 12-month low of $6.79 and a 12-month high of $19.58.

Insider Buying and Selling

In other news, CFO Nelson Sun bought 10,000 shares of the company’s stock in a transaction dated Friday, February 14th. The shares were acquired at an average cost of $16.00 per share, with a total value of $160,000.00. Following the completion of the transaction, the chief financial officer now directly owns 99,484 shares in the company, valued at approximately $1,591,744. The trade was a 11.18 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Tien-Li Lee bought 16,542 shares of Aardvark Therapeutics stock in a transaction dated Friday, February 14th. The stock was acquired at an average price of $16.00 per share, with a total value of $264,672.00. Following the acquisition, the chief executive officer now directly owns 1,496,175 shares of the company’s stock, valued at approximately $23,938,800. This represents a 1.12 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

About Aardvark Therapeutics

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.